Zymeworks Inc. [ZYME] - Zymeworks / Theravance Biopharma merger

Zymeworks Inc. has entered into a definitive merger agreement to acquire Theravance Biopharma, Inc. for $17.00 per share in cash, plus one contingent value right, with Theravance becoming a wholly owned subsidiary of Zymeworks.

View source filing ↗